Nov 1, 2021 · A bifunctional PD-L1-ADC was developed based on the use of endocytic PD-L1 antibody Atezolizumab, exhibiting potent cytotoxicity (EC50 = 9.75 ∼ 11.94 nM) and immune activation effect. Bifunctional PD-L1-ADC may promote the …

Aug 26, 2022 · SGN-PDL1V is a PD-L1-directed ADC currently under preclinical investigation that consists of an anti-PD-L1 antibody conjugated to a vedotin drug ligand. The vedotin drug linker consists of a microtubule disruptor, monomethyl auristatin …

Mar 20, 2025 · The combination of an ADC and a programmed death-1 (PD-1)/PD-L1 inhibitor has been a promising treatment regimen for TNBC. In the phase 2 platform sequential multiple assignment randomized I-SPY2.2 trial evaluating neoadjuvant Dato-DXd for early-stage breast cancer, the investigators defined response-predictive subtypes (RPS) by a combination ...

Aug 24, 2020 · PD-L1 antibody drug conjugate (ADC) for selective chemo-guided immune modulation of tumor has also been developed which has shown promising tumor suppression potency. 4 MAbs that could bind to...

Feb 20, 2025 · Pfizer’s PD-L1 ADC, SGN-PDL1V, is currently leading the field, with plans to initiate a pivotal Phase 3 clinical trial for first-line treatment of head and neck squamous cell carcinoma (HNSCC) and second-line or later treatment of non-small cell lung cancer (NSCLC).

This BsADC selectively targets the immune checkpoints programmed cell death ligand-1 (PD-L1) and B7-H3, and the precise delivery of the small-molecule toxin monomethyl auristatin E. Results Our findings demonstrated that the BsADC outperformed its bispecific antibody and PD-L1 or B7-H3 ADC counterparts, particularly in terms of in vitro/in vivo ...

HLX43 is a novel PD-L1-targeting ADC consisting of an engineered anti-PD-L1 humanised IgG1 antibody linked to a camptothecin-based toxin, with a drug to antibody ratio of 8. Our innovative linker-payload is activated preferentially in the tumour microenvironment, enabling its tumour-specific release of the toxin without needing internalisation ...

The proposed MOAs of PDL1V reflect the hallmarks of vedotin-based ADCs: MMAE-induced cytotoxicity against PD-L1-expressing tumor cells, immunogenic cell death (ICD), and bystander effect 1; The PDL1V antibody has been designed to enable targeting of PD-L1 with an ADC through engineering for potential of increased internalization and payload ...

Feb 28, 2025 · PD-L1 expression in tumor samples was assessed by the Ventana PD-L1 Assay (SP263, Ventana Medical Systems, Inc.). ... Zhou L, et al. RC48-ADC combined with toripalimab, an anti-PD-1 monoclonal antibody (ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): preliminary results of a phase Ib/II study. ...

Sep 13, 2024 · Pfizer subsidiary Seagen is developing the PD-L1-directed ADC, dubbed SGN-PDL1V or PF-0804605. The drug comprises a PD-L1 monoclonal antibody attached to the cytotoxic payload monomethyl auristatin E, or MMAE.